Pfizer (PFE)

Pfizer's revenue didn't grow, but the mix underneath it changed a lot.

The healthcare stock may finally have the catalyst that it needs to take off before the end of the year.

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q3 2026 results exceeding the market’s revenue expectations, but revenue was flat year on year at $1...

Pfizer stock slipped a fraction early Tuesday, but the company raised its guidance for the year and named a new CFO.

Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2026 and raised its full-year 2026 guidance(2) for both Revenues and Adjusted(3) diluted EPS.

Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026. Cecile has served as interim Chief Financial Officer since August 16, 2026, steering the company’s financial operations, execution and strategic planning.

Panama City, Guanacaste in Costa Rica and Lagos, Portugal top one investor's list for rental income and long-term growth, with Portuguese mortgages from 2.6%.

The market for GLP-1 drugs is forecast to explode. It may be understated still.

NEW YORK, NY - November 2, 2026 - Michael Benabib, the corporate headshot photographer in New York City behind Executive Photos NYC, is expanding studio and on-location executive portrait sessions that apply the editorial approach he developed photographing for Forbes, The New York Times, Vanity Fair and The Wall Street Journal. As a corporate headshot photographer in New York City for more than 30 years, Benabib now photographs Fortune 500 executives, attorneys, physicians and full leadership teams on location and at his studio at 275 Fifth Avenue in Midtown Manhattan.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as...

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before market open. Here’s what to expect. Pfizer beat analysts’ reven...

Pfizer's post-COVID comeback is still only in the early stages.

Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attributed the performance to increased Sanofi collaboration revenue and continued growth from DUPIXENT,

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

The stocks listed here yield up to 5.8%.

These three high-yield dividend stocks could surge once investors realize they've overreacted to recent headwinds.

Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment with anti-CD38 therapy (daratumumab or isatuximab) and lenalidomide.

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (PC) with homologous recombination repair (HRR) gene mutations, including both BRCA and non-BRCA mutations. mAPMN/S is also known as metastatic hormone-sensitive prostate cancer (mHSPC). This approval makes TALZENNA, an oral poly ADP-ribose polymerase (PARP inhibitor), plus XTANDI, an androgen receptor pathway inhibitor (ARPI), available in an earlier line, providing an opportunity to delay disease progression at a critical stage when more patients may experience greater benefit.

EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:MRNA),(NASDAQ:IOVA),(NASDAQ:GMAB),(NYSE:PFE) EQNX::TICKER_END

Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. In the study, a four-dose series of 25vPnC elicited robust immune responses against all 25 serotypes and showed safety and tolerability comparable to four doses of PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine). These findings were shared today in an oral presentation at IDWeek 2026 in Washington, D.C.1

Pfizer has a plan to bounce back from recent obstacles.